12345...10...


Nanobiotechnology Applications, Markets and Companies, 2017-2021 & 2026 – GlobeNewswire (press release)

Dublin, Sept. 07, 2017 (GLOBE NEWSWIRE) — The “Nanobiotechnology Applications, Markets and Companies” report from Jain PharmaBiotech has been added to Research and Markets’ offering.

The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. It includes some of the physical forms of energy such as nanolasers. Some of the technologies are scaling down such as microfluidics to nanofluidic biochips and others are constructions from bottom up. Application in life sciences research, particularly at the cell level sets the stage for role of nanobiotechnology in healthcare in subsequent chapters.

An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development – from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.

Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems. Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included.

Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress. There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2016. The largest expansion is expected between the years 2021 and 2026.

Profiles of 252 companies, out of over 500 involved in this area, are included in the last chapter along with their 183 collaborations.The report is supplemented with 51 Tables, 31 figures and 800 references to the literature.

Key Topics Covered:

Part I: Applications & Markets

1. Introduction

2. Nanotechnologies

3. Nanotechnologies for Basic Research Relevant to Medicine

4. Nanomolecular Diagnostics

5. Nanopharmaceuticals

6. Role of Nanotechnology in Biological Therapies

7. Nanodevices & Techniques for Clinical Applications

8. Nanooncology

9. Nanoneurology

10. Nanocardiology

11. Nanopulmonology

12. Nanoorthopedics

13. Nanoophthalmology

14. Nanomicrobiology

15. Miscellaneous Healthcare Applications of Nanobiotechnology

16. Nanobiotechnology and Personalized Medicine

17. Nanotoxicology

18. Ethical and Regulatory Aspects of Nanomedicine

19. Research and Future of Nanomedicine

20. Nanobiotechnology Markets

21. References

Part II: Companies

22. Nanobiotech Companies

For more information about this report visit https://www.researchandmarkets.com/research/xnnnck/nanobiotechnology

See the original post here:
Nanobiotechnology Applications, Markets and Companies, 2017-2021 & 2026 – GlobeNewswire (press release)

Global Nanomedicine Industry 2017 Market Growth, Trends and Demands Research Report – MENAFN.COM

(MENAFN Editorial) iCrowdNewswire – Sep 4, 2017

The Global Nanomedicine Market 2017 Industry Research Report’ report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the Global major industry players in detail.

The Global Nanomedicine Market Research Report 2017 renders deep perception of the key regional market status of the Nanomedicine Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, #China and Japan.

Complete report on Nanomedicine market report spread across 116 pages, profiling 12 companies and supported with tables and figuresavailable @

The report on ‘Global Nanomedicine Market is a professional report which provides thorough knowledge along with complete information pertaining to the Nanomedicine industry propos classifications, definitions, applications, industry chain summary, industry policies in addition to plans, product specifications, manufacturing processes, cost structures, etc.

The potential of this industry segment has been rigorously investigated in conjunction with primary market challenges. The present market condition and future prospects of the segment has also been examined. Moreover, key strategies in the market that includes product developments, partnerships, mergers and acquisitions, etc., are discussed. Besides, upstream raw materials and equipment and downstream demand analysis is also conducted.

Report Includes:-

The report cloaks the market analysis and projection of ‘Nanomedicine Market on a regional as well as global level. The report constitutes qualitative and quantitative valuation by industry analysts, first-hand data, assistance from industry experts along with their most recent verbatim and each industry manufacturers via the market value chain. The research experts have additionally assessed the in general sales and revenue generation of this particular market. In addition, this report also delivers widespread analysis of root market trends, several governing elements and macro-economic indicators, coupled with market improvements as per every segment.

For any Inquire before buying @

Global Nanomedicine market competition by top manufacturers/players, with Nanomedicine sales volume, Price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including: GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., SigmaTau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A

The report is generically segmented into six parts and every part aims on the overview of the Nanomedicine industry, present condition of the market, feasibleness of the investment along with several strategies and policies. Apart from the definition and classification, the report also discusses the analysis of import and export and describes a comparison of the market that is focused on the trends and development. Along with entire framework in addition to in-depth details, one can prepare and stay ahead of the competitors across the targeted locations. The fact that this market report renders details about the major market players along with their product development and current trends proves to be very beneficial for fresh entrants to comprehend and recognize the industry in an improved manner. The report also enlightens the productions, sales, supply, market condition, demand, growth, and forecast of the Nanomedicine industry in the global markets.

Buy a copy of this report @

Every region’s market has been studied thoroughly in this report which deals with the precise information pertaining to the Marketing Channels and novel project investments so that the new entrants as well as the established market players conduct intricate research of trends and analysis in these regional markets. Acknowledging the status of the environment and products’ up gradation, the market report foretells each and every detail.So as to fabricate this report, complete key details, strategies and variables are examined so that entire useful information is amalgamated together for the understanding and studying the key facts pertaining the global Nanomedicine Industry. The production value and market share in conjunction with the SWOT analysis everything is integrated in this report.

Table of Contents

1 Nanomedicine Market Overview 2 Global Nanomedicine Market Competition by Manufacturers 3 Global Nanomedicine Capacity, Production, Revenue (Value) by Region (2011-2016) 4 Global Nanomedicine Supply (Production), Consumption, Export, Import by Regions (2011-2016) 5 Global Nanomedicine Production, Revenue (Value), Price Trend by Type 6 Global Nanomedicine Market Analysis by Application 7 Global Nanomedicine Manufacturers Profiles/Analysis

8 Nanomedicine Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Nanomedicine Market Forecast (2016-2021) 13 Research Findings and Conclusion

About Us

Deep Research Reportsis digital database of syndicated market reports for global and #China industries. These reports offer competitive intelligence data for companies in varied market segments and for decision makers at multiple levels in these organizations. We provide 24/7 online and offline support to our customers.

Connect us

Hrishikesh Patwardhan

Corporate Headquarters

2nd floor, metropole,

Next to inox theatre,

Bund garden road,Pune-411001.

1 888 391 5441

MENAFN0509201700703403ID1095819074

Read more here:
Global Nanomedicine Industry 2017 Market Growth, Trends and Demands Research Report – MENAFN.COM

Nanomedicine Research Journal

Nanomedicine Research Journal (Abbreviation: Nanomed Res J)

is an international, open access, peer-reviewed, electronic and print quarterly publication released by the Iranian Society of Nanomedicine (ISNM). Nanomedicine Research Journal publishes original research articles, review papers, mini review papers, case reports and short communications covering a wide range of field-specific and interdisciplinary theoretical and experimental results related to applications of nanoscience and nanotechnology in medicine including, but not limited to, diagnosis, treatment, monitoring, prediction and prevention of diseases, tissue engineering, nano bio-sensors, functionalized carriers and targeted drug delivery systems.

* Publication process of manuscripts submitted to Nanomed Res J is free of charge.

To see Acceptance timeline Please follow the link below:

Acceptance Timeline Diagram

About the publisher

Founded in 2011 by the leading ofSchool of Advanced Technologies in medicine (SATiM),Tehran University of Medical Sciences (TUMS) and Iran Nanotechnology Initiative Council, the Iranian Society of Nanomedicine (ISNM) attempts to promote and develop medical nanotechnology in Iran. For more information about the publisher, please visit us at http://isnm.ir/en/.

Read the original:
Nanomedicine Research Journal

Molecular nanosubmarines can target and kill specific cancer cells – New Atlas

In 2015, scientists from Rice University revealed they had created light-driven nanosubmarines. These tiny molecular machines were activated by ultraviolet light and based on earlier work from Nobel laureate Bernard Feringa, whose ground-breaking research won the prize for chemistry in 2016. These single-molecule machines have now been shown to be able to target, and drill into, specific cancer cells, paving the way for a variety of highly targeted future nanomedicine treatments.

These molecular machines consist of 244 atoms with a tail-like propeller that creates propulsion when exposed to UV light. After proving the concept worked back in 2015, the team moved on to exploring whether the molecular motor could penetrate an individual cell.

“We thought it might be possible to attach these nanomachines to the cell membrane and then turn them on to see what happened,” explains chemist James Tour.

First the team needed to attach the molecular motor to a component that allowed it to target a specific cell. In these early experiments a peptide was utilized that drove the molecule to attach itself to the membrane of human prostate cancer cells. The molecules were shown to effectively locate and attach to the targeted cells, but not drill into them until specifically triggered by UV light. Once triggered, the motors spun up to two to three million rotations per second to break through the cell membrane and kill the cell within one to three minutes.

The obvious challenge that needs to be overcome is to develop an activation trigger other than ultraviolet light, which currently limits the molecular motors to being controllable when concentrated at the surface of tissue. Other triggers are currently being investigated, with near infra-red (IR) light looking like the best option to control these motors when delivered deep into a body.

“In this process, the motor will absorb two photons simultaneously and get enough energy to start the rotor,” says Gufeng Wang, a chemist on the Rice University team. “Since near IR light has deep penetration depth, we are no longer limited to the surface of the tissue.”

There is much work that still needs to be done before these molecular motors become a real, clinical treatment, but there are a variety of exciting outcomes this technology promises. As well as targeting and destroying cancer cells, the molecular motors could be utilized to deliver drugs directly into diseased cells.

As well as working on additional activation mechanisms, the team is embarking on a series of small animal tests to examine the effectiveness of the molecules on living organisms.

“The researchers are already proceeding with experiments in microorganisms and small fish to explore the efficacy in-vivo,” says Tour. “The hope is to move this swiftly to rodents to test the efficacy of nanomachines for a wide range of medicinal therapies.”

The research was published in the journal Nature and the video below provides a closer look at the team’s breakthrough.

Source: Rice University

Original post:
Molecular nanosubmarines can target and kill specific cancer cells – New Atlas

Nanomedicine Market Growth Opportunities for Distributers 2017 – Equity Insider (press release)

Global Nanomedicine Market Research Report 2017 to 2022 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Nanomedicine Market.

Companies Mentioned are GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A.

Primary sources are mainly industry experts from core and related industries, and suppliers, manufacturers, distributors, service providers, and organizations related to all segments of the industrys supply chain. The bottom-up approach was used to estimate the global market size of Nanomedicine based on end-use industry and region, in terms of value. With the data triangulation procedure and validation of data through primary interviews, the exact values of the overall parent market, and individual market sizes were determined and confirmed in this study.

Sample/Inquire at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017/inquiry

This report segments the global Nanomedicine market on the basis of types Regenerative Medicine, In-vitro & In-vivo Diagnostics, Vaccines, Drug Delivery. On the basis of application Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology.

Essential points covered in Global Nanomedicine Market 2017 Research are:-

This independent 116 page report guarantees you will remain better informed than your competition. With over 170 tables and figures examining the Nanomedicine market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2022.

The global Nanomedicine market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Browse Full Report at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Storage Area Network Switch in these regions, from 2012 to 2022 (forecast), covering

by Regions

The report provides a basic overview of the Nanomedicine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. Whats more, the Nanomedicine industry development trends and marketing channels are analyzed.

The research includes historic data from 2012 to 2016 and forecasts until 2022 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Nanomedicine on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Nanomedicine Market and assist manufacturers and investment organization to better grasp the development course of Nanomedicine Market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

There are 15 Chapters to deeply display the global Nanomedicine market.

Chapter 1, to describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Nanomedicine, with sales, revenue, and price of Nanomedicine, in 2016and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Nanomedicine, for each region, from 2012to 2017;

Chapter 5, 6, 7,8and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Nanomedicine market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;

Chapter 13, 14 and 15, to describe Nanomedicine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

View post:
Nanomedicine Market Growth Opportunities for Distributers 2017 – Equity Insider (press release)

Eun Ji Chung Receives 2017 AIChE 35 Under 35 Award – USC Viterbi School of Engineering (press release) (blog)

The goal-setting Assistant Professor rounds out a successful 2017 with an early career honor from the American Institute of Chemical Engineers

Eun Ji Chung is a Gabilan Assistant Professor in the Department of Biomedical Engineering and recipient of a 2017 AIChE 35 Under 35 Award. Photo credit/Michelle Henry

To describe Eun Ji Chung as goal-oriented might be the understatement of the year.

Chung, a Gabilan Assistant Professor in the USC ViterbiDepartment of Biomedical Engineering, has racked up an impressive number of achievements in 2017 alone. In addition to receiving a 2017 USC Stem Cell Eli and Edythe Broad Innovation Award, she was selected for the 2017 Emerging Investigator Issue of the journal Biomaterials Science and a 2017 Biomedical Engineering Society (BMES) Career Development Award.

This summer, Chung found out that she was being honored with a 2017 American Institute of Chemical Engineers (AIChE) 35 Under 35 Award for her exceptional work in bioengineering.

Bright-Eyed Youth

People like Chung tend to be driven at a young age, perhaps ever since birth.

As an undergraduate at Scripps College, she pursued a degree in molecular biology and conducted biology research in unicellular organisms. While there, her interests became more patient-focused.

While I had a strong foundation in biology, I wanted to pursue a field that could help human health and patients, Chung said. This led me to pursue biomedical engineering as a graduate student (at Northwestern University) and choose a lab that focused on biomaterials research.

During her post-doctoral training at the University of Chicago, Chung achieved a goal she ranks as her proudest professional achievement: an NIH K99/R00 Pathway to Independence Award for her proposal to develop a nanoparticle that could be delivered intravenously and detect atherosclerosis, a potentially fatal build-up of plaque in the arteries. The nanodevice could also deliver therapeutics and signal whether the treatment was successful.

The first time she applied for the award, her application was streamlined and rejected, but she was determined to succeed.

Despite the statistics and critics confirming the high likelihood of being streamlined again in the resubmission, I persisted, addressed all of the reviewer comments diligently, and received a top score the second time around, Chung said.

The Bioengineer

In her lab, Chung and her research group investigate molecular design, nanomedicine and tissue engineering to generate biomaterial strategies for clinical applications. She is emphatic about working with her students (both undergraduate and graduate) and postdoctoral trainees toward their own individual aspirations.

While it takes continuous dialogue, planning and learning together, every small milestone that we achieve towards the larger goals makes me feel proud and gives me a sense of pride in my work and role, Chung said.

In the future, Chungs research goals include providing cost-efficient nanodiagnostics and therapeutics for patients that are not well-understood or overlooked. She believes that to achieve this goal requires an interdisciplinary team of scientists, clinicians and trainees. This belief makes Chung an excellent fit as one of the faculty members joining the new USC Michelson Center for Convergent Bioscience when it opens this November.

In order to train the next generation of the STEM workforce, I hope to inspire students and convey biomedical engineering and biomaterials research as both tangible and compelling, Chung said.

The Juggling Act

Chung describes her pursuit of both an ambitious academic career and family life as a juggling act that requires frequent fine-tuning.

She has even developed her own system of goal attainment that all starts with putting a pencil to paper.

Every December, I write out my career and family goals for the upcoming year, as well as any additional personal goals that I might have, and categorize them into a timeline of seasons, Chung said. In addition, I have longer, five-year goals. This way, I can approach ambition in a holistic manner.

The rest is here:
Eun Ji Chung Receives 2017 AIChE 35 Under 35 Award – USC Viterbi School of Engineering (press release) (blog)

Impact of Existing and Emerging Europe Nanomedicine Market – MilTech

The global Nanomedicine Market size was estimated at USD XX billion in 2017. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders is expected to bolster growth in this market.

Download Sample Pages @http://www.kminsights.com/request-sample-33081

Nanotechnology involves the miniaturization of larger structures and chemicals at nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2022.

Expected developments in nanorobotics owing to the rise in funding from the government organizations is expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues is anticipated to drive progress through to 2022.

Ability of the nanotechnology to serve in diagnostics as well as the therapeutic sector at the same time as a consequence of its characteristic principle to is anticipated to augment research in this sector. Furthermore, utilization of DNA origami for healthcare applications is attributive for the projected growth.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others.

On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics.

The global market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth.

Download Sample Pages @http://www.kminsights.com/request-sample-33081

Contact:

Mr.Mannansales@kminsights.com+1 (888) 278-7681

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Visit link:
Impact of Existing and Emerging Europe Nanomedicine Market – MilTech

Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor … – PR NewsChannel (press…

Michelle Bradbury MD, PhD, who is a Professor of Radiology, Director of Intraoperative Imaging, and Co-Director of an National Cancer Institute awarded Nanomedicine Center (MSK-Cornell Center for Translation of Cancer Nanomedicines), has been named a 2017 Top Doctor in New York City, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care.

Dr. Michelle S. Bradbury is a highly experienced physician who has been in practice for over two decades. Her career in medicine started in 1997, when she graduated from the George Washington University School of Medicine and Health Sciences in Washington, D.C. An internship, residency and then fellowship followed, all completed at Wake Forest University in Winston-Salem, North Carolina. Dr. Bradbury also holds a Doctor of Philosophy Degree from the Massachusetts Institute of Technology.

Dr. Bradbury is certified by the American Board of Radiology in both Diagnostic Radiology and Neuroradiology. She is particularly renowned, however, as a leading expert in nanomedicine and in neuroradiology, using CT and MRI imaging of the brain, neck and spine to diagnose conditions of the nervous system. Alongside her work in this field she has been at the forefront of nanomedicine research and clinical trials.

Dr. Bradbury keeps up to date with the latest advances in her field through her active membership of professional organizations including the American College of Radiology, the World Molecular Imaging Congress, and the American Society of Nanomedicine. Her expertise and dedication makes Dr. Michelle S. Bradbury a very deserving winner of a 2017 Top Doctor Award.

About Top Doctor Awards

Top Doctor Awards specializes in recognizing and commemorating the achievements of todays most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors

View post:
Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor … – PR NewsChannel (press…

New report shares details about Europe’s nanomedicine market – WhaTech

The global nanomedicine market size was estimated at USD XX billion in 2017. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders is expected to bolster growth in this market.

Nanotechnology involves the miniaturization of larger structures and chemicals at nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2022.

Download Sample Pages @www.kminsights.com/request-sample-33081

Expected developments in nanorobotics owing to the rise in funding from the government organizations is expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues is anticipated to drive progress through to 2022.

Ability of the nanotechnology to serve in diagnostics as well as the therapeutic sector at the same time as a consequence of its characteristic principle to is anticipated to augment research in this sector. Furthermore, utilization of DNA origami for healthcare applications is attributive for the projected growth.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others.

On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics.

This report studies sales (consumption) of Nanomedicine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, the top player coveringAffilogicLTFNBergmannstrostGrupo PraxisBiotechrabbitBraccoMaterials Research?CentreCarlina technologiesChemConnectionCIC biomaGUNECIBER-BBNContiproCristal TherapeuticsDTIEndomagneticsFraunhofer ICT-IMMTecnaliaTeknikerGIMACIMDEAIstec CNRSwedNanoTechVicomtechVITO NV

The global market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth.

In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.

Download Sample Pages @www.kminsights.com/request-sample-33081

View original post here:
New report shares details about Europe’s nanomedicine market – WhaTech

Growth in the Global Nanomedicine Market 2017-2021 trends, forecasts, analysis – satPRnews (press release)

Global Nanomedicine Market 2017-2021

This Nanomedicine market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Download sample pages of this report:http://tinyurl.com/y7bs9wea

Data integration and capabilities are analyzed to support the findings and study the predicted geographical segmentations. Various key variables and regression models were considered to calculate the trajectory of Nanomedicine market. Detailed analysis is explained and given importance to with best working models.

Geographically, the segmentation is done into several key regions like North America, Middle East & Africa, Asia Pacific, Europe and Latin America. The production, consumption, revenue, shares in mill UDS, growth rate of Nanomedicine market during the forecast period of 2017 to 2021 is well explained.

The ongoing market trends of Nanomedicine market and the key factors impacting the growth prospects are elucidated. With increase in the trend, the factors affecting the trend are mentioned with perfect reasons. Top manufactures, price, revenue, market share are explained to give a depth of idea on the competitive side.

Each and every segment type and their sub types are well elaborated to give a better idea about this market during the forecast period of 2017 to 2021 respectively.

Download sample pages of this report:http://tinyurl.com/y7bs9wea

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

Mr. Mannansales@kminsights.com+1 (888) 278-7681

More:
Growth in the Global Nanomedicine Market 2017-2021 trends, forecasts, analysis – satPRnews (press release)

Director of The Baby Place at Park Ridge Health earns doctorate in nursing practice – Mountain Xpress (blog)

Press release:

Park Ridge Health is celebrating the success of Beth Cassidy, DNP, MSN, RNC-OB, NE-BC, Director of The Baby Place at Park Ridge Health who recently earned her Doctorate of Nursing Practice degree.Cassidy has been the director of The Baby Place at Park Ridge Health since 2011. In her time as director, The Baby Place has earned national recognition for its exemplary care for mothers and babies across Western North Carolina, including the Womens Choice Award as one of Americas Best Hospitals for Obstetrics.Cassidy says she embarked on the journey to earn her doctorate because of her love of learning and her love for empowering her team. As a unit director in a small facility, which I prefer, you have to be an educator, said Cassidy. My team supported me through the two full years of doctorate work in anticipation of how we would turn it around to be directly applicable to each of them and their goals of expanding their skills.Park Ridge Health makes it a priority to discover the goals each of our employees may have for their lives and then encourages and empowers them to achieve those goals, said Jimm Bunch, Park Ridge Health President and CEO. Beths determination and drive to expand her skills as a caregiver and as a nursing leader are an inspiration, not only to her team, but to the entire Park Ridge Health family.The Baby Place at Park Ridge Health has become the labor and delivery center of choice for hundreds of families across Western North Carolina. Cassidy works as part of a caring team of Physicians, Nurses, Midwives, Lactation Consultants, Childbirth Educators and other support personnel to bring families the best possible care, so they can focus on one of the most important experiences of their lives. The Baby Place at Park Ridge Health cares for women through their choices which range from traditional delivery, to natural labor, to midwifery. In 2016, Cassidy and her team helped welcome nearly 650 babies into the world. To learn more about The Baby Place at Park Ridge Health, call 855.PRH.LIFE (855.774.5433) or visit myPRH.com.About Park Ridge Health: Founded in 1910, Park Ridge Health is dedicated to meeting the health care needs of our growing communities, providing high-quality, compassionate care in a Christian environment. In 1984, Park Ridge Health became a member of Adventist Health System, a family of 45 exceptional, faith-based hospitals across the country that operate independently to deliver care and services that best meet the needs of their communities. Leading the way in many medical firsts for the region, Park Ridge Health is the first hospital in Western North Carolina to offer nanomedicine in the operating room with the Nanolock Spinal technology and the only hospital in the region with the Pro-Axis Spine Surgery table. Park Ridge Health provides personalized care at more than 30 locations, offering a dedicated network of more than 250 physicians and providers, cardiac care & rehabilitation, emergency services, nationally awarded cancer care, state-of-the-art surgical care, full-service orthopedic care, an award-winning labor & delivery experience, and a full range of imaging services. For more information about Park Ridge Health or to find a physician, please visit parkridgehealthor call 855.PRH.LIFE (855.774.5433).

Excerpt from:
Director of The Baby Place at Park Ridge Health earns doctorate in nursing practice – Mountain Xpress (blog)

Are nano drug delivery and telehealth solutions a deadly combo for disease? – EPM Magazine

Incorporating telehealth solutions into new drug delivery technologies like nanomedicines can potentially give pharmaceuticals the edge they need to win the fight against disease.

Creating drug delivery systems that utilise telehealth solutions like smartphone technologies, Bluetooth, IoT, wearable technologies, and AI would help pharmaceutical companies save money in clinical trials by reducing the financial burden caused by poor medical adherence and provide better patient outcomes through real-time data analysis. Telehealth solutions provide physicians and clinical trial scientists direct access to their patient, and can provide them with valuable data that will improve their performance and the patients health. Access to real-time patient health data is an opportunity for pharmaceutical companies to develop a range of smart drug delivery systems that could potentially change the way an estimated 50% of the population deal with their chronic diseases.

With large numbers living with some form of chronic disease, pharmaceutical companies must incorporate telehealth tech into their drug delivery systems to collect real-time data and use the data to improve patient treatment, clinical trial outcomes and apply the data for further research.

The drug delivery systems available in todays market are honestly not that impressive. A Bluetooth-enabled inhaler, smart automatic injectors, and smart pills are definitely technologies that benefit patient care but lack innovative pizzazz. Bluetooth technology was first introduced in mobile phones in 2000. It has taken 17 years to implement the data-gathering technology into an inhaler/auto injector, often at times requiring user actions like downloading from an SD card. I am surprised it has taken this long for pharma to get where it is today, but there is truly hope on the horizon, with recent advancements in nanotechnology.

The future of pharmaceuticals and population health lies in the utilisation of telehealth solutions like the Internet of Nano Things (IoNT), wearables, smartphones and the latest drug delivery tech likesmart nanoplatforms, nanoparticles/nanomedicines, and nanosensors. These recent technological advancements in drug delivery should change the way we understand and cure diseases.

Northwestern University has developed a nanoplatform that can assess the effectiveness of nanomaterials in regulating gene expression. The nanoplatform allows scientists to observe nanomedicines and particle behaviour in an in vivo setting. Theres no doubt that the relationship between nanomedicines and IoNT is inevitable however there are issues like patient health risks and security that must be taken into account.

Whenever the internet is involved, the issue of security should be raised. Are nanomedicines saving patients lives, while also putting them at risk of body hacking? Although programmable particles are sending signals from within the patients body and providing beneficial information for the doctor/scientist, the idea that a signal can be hacked is a horrific reality. Nanoparticle manipulation is possible by gaining access to the particles using ultrasound and electromagnetic field waves making hacking feasible but extremely difficult and complex. The next question is what happens to the nanoparticles after treatment? Will they pose a later threat and become an access point for hackers?

Nanomedicines, after entering the human body, travel throughout reaching the organs, the bloodstream, the lungs and even crossing the semi-permeable membranes into cells delivering the drugs to exactly the right place at the right time. Their disbursement depends on size and programming. Nanoparticles are metal-based, carbon-based, composites, and dendrimers, and are excreted from the body via faeces and urine. The liver and spleen can also decompose them, however up to 30% can remain in the body for an extended period of time and potentially become an access point for hacking.

Combining telehealth solutions and nanomedicines will benefit the populations health by presenting effective treatments for chronic and deadly pathologies and provide scientists and doctors previously unattainable data for analysis. This previously elusive data has become available thanks to Northwestern Universitys Nanoplatform, which successfully provides imaging of the nanomedicines effectiveness on the MGMT gene, a chemo-resistant cancer gene. This data has already provided a better understanding of the nanomedicines mechanics and provided researchers with the best time, after treatment with nanomedicines, to administer chemotherapy.

Nanoparticles appear to be a solution that can improve the health of the population, however there are still potential risks for patients. Although most nanoparticles are tested in labs and in vitro, a few potential health risks have been observed. Risks like the creation of a protein corona (a shifting population of different molecules) can influence the immune defence system and mistakenly allow the corona to penetrate good non-targeted tissues. The clumping of protein molecules can also be linked to multiple pathologies, including amyloidosis. Some nanoparticles have also been linked to genetic mutations, DNA damage, and chromosomal alterations, however they are rarely attributed to all three at once. It is quite clear that more research and testing is required to truly understand the future of nanomedicine and its effects on the human body.

Nanomedicines target a specific area within the body, can delay activation and have the potential to relay real-time data for analysis. Scientists and doctors can finally have a real-time view of their treatments and understand the pathology and its interaction with the medicines, leading to data that will help the healthcare industry save lives, defeat disease, and save money. The benefits in combining telehealth solutions with nano drug delivery systems is evident and it is the colossal leap forward that the industry has been looking for in the never-ending fight with diseases like cancer.

See the article here:
Are nano drug delivery and telehealth solutions a deadly combo for disease? – EPM Magazine

Lungs in Space – Texas Medical Center (press release)


Texas Medical Center (press release)
Lungs in Space
Texas Medical Center (press release)
This investigation represents the third of four collaborative projects currently active at the HMRI's Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI

The rest is here:
Lungs in Space – Texas Medical Center (press release)

Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

Global Nanomedicine Market Research Report 2016

2016 Global Nanomedicine Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Nanomedicine industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

Download sample pages of this report: https://goo.gl/cBLFx6

The report firstly introduced the Nanomedicine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with: 1.) basic information; 2.) the Asia Nanomedicine industry; 3.) the North American Nanomedicine industry; 4.) the European Nanomedicine industry; 5.) market entry and investment feasibility; and 6.) the report conclusion.

Download sample pages of this report: https://goo.gl/cBLFx6

About Us:

Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

sales@kminsights.com

+1 (888) 278-7681

The rest is here:
Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

Growth in Nanomedicine market-2017 trends, forecasts, analysis … – satPRnews (press release)

The report firstly introduced the Nanomedicine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Download sample pages of this report: http://www.kminsights.com/request-sample-1892

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism.

The ongoing market trends of Nanomedicine market and the key factors impacting the growth prospects are elucidated. With increase in the trend, the factors affecting the trend are mentioned with perfect reasons. Top manufactures, price, revenue, market share are explained to give a depth of idea on the competitive side.

Each and every segment type and their sub types are well elaborated to give a better idea about this market during the forecast period of 2017respectively.

Download sample pages of this report: http://www.kminsights.com/request-sample-1892

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:sales@kminsights.com+1 (888) 278-7681

Read more:
Growth in Nanomedicine market-2017 trends, forecasts, analysis … – satPRnews (press release)

siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

Early phase Northwestern Medicine research published in the journal Proceedings of the National Academy of Sciences has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer-based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor-initiating cells (BTICs).

BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy, explained the studys first author, Dou Yu, MD, PhD, research assistant professor of Neurological Surgery.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA) short sequences of RNA molecules that reduce the expression of specific cancer-promoting proteins directly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind, said Yu, who collaborated on the research with principal investigator Maciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patients tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissues but not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling, Yu said. Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits.

The strategy could also apply to other medical conditions related to the central nervous system not just brain tumors.

Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform, Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor-initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer, Lesniak summed up.

This article has been republished frommaterialsprovided by Northwestern University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Dou Yu, Omar F. Khan, Mario L. Suv, Biqin Dong, Wojciech K. Panek, Ting Xiao, Meijing Wu, Yu Han, Atique U. Ahmed, Irina V. Balyasnikova, Hao F. Zhang, Cheng Sun, Robert Langer, Daniel G. Anderson, Maciej S. Lesniak. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proceedings of the National Academy of Sciences, 2017; 201701911 DOI: 10.1073/pnas.1701911114

View original post here:
siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

Space travel can cause a lot of stress on the human body as the change in gravity, radiation and other factors creates a hostile environment. While much is known about how different parts of the body react in space, how lungs are affected by spaceflight has received little attention until now, say researchers at The University of Texas Medical Branch at Galveston and Houston Methodist Research Institute.

That will change, though, once their research project, which aims to grow lungs in space, reaches the International Space Station. UTMB and HMRI researchers say what they learn from the study could have real implications for astronauts, as well as those still on Earth, and could lead to future therapeutics.

“We know a lot about what happens in space to bones, muscle, the heart and the immune system, but nobody knows much about what happens to the lungs,” said Joan Nichols, a professor of Internal Medicine and Microbiology and Immunology, and associate director for research and operations for the Galveston National Laboratory at UTMB. “We know that there are some problems with lungs in space flight, but that hasn’t been closely looked into. We hope to find out how lung cells react to the change in gravity and the extreme space environment, and then that can help us protect astronauts in space, as well as the lungs of regular people here on Earth.”

This investigation represents the third of four collaborative projects currently active at the HMRI’s Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI, focuses on the investigation of nanotechnology-based strategies for medicine on Earth and in space. The research is supported by the Center for the Advancement of Science in Space, NASA and HMRI.

Scientists from UTMB and HMRI prepared bioreactor pouches that include lung progenitor and stem cells and pieces of lung scaffolding. The scaffolding is the collagen and elastin frame on which lung cells grow. Space X successfully launched the payload containing these pouches Aug. 14 on its 12th Commercial Resupply Services mission (CRS-12) from NASA’s Kennedy Space Center in Florida and is expected to arrive at the International Space Station Aug. 16. Once on the ISS, the cells are expected to grow on the scaffold in a retrofitted bioreactor.

Once the lung cells have returned to Earth, researchers will look for the development of fibrosis, the structure of the tissues and the response of immune cells, among other changes and damage that could occur to the lung cells. Lung injuries have been found to accelerate in space, and it is through close study of those cells that therapeutics hopefully could be developed.

Nichols and Dr. Joaquin Cortiella, a professor and director of the Lab of Tissue Engineering and Organ Regeneration at UTMB, have successfully grown lungs in their lab in Galveston, but now they will see if astronauts can do the same in zero gravity. Jason Sakamoto, affiliate professor and former co-chair of the Department of Nanomedicine at HMRI, has applied his novel organ decellularization process and nanotechnology-based delivery systems to support this overall lung regeneration effort.

“We have experience working with the Center for the Advancement of Science in Space to study our nanotechnologies in action on the International Space Station,” Grattoni said. “However, we are extremely excited to be a part of this clinical study, since it may play a pivotal role in how we approach future space travel in terms of preserving astronaut health. What we learn during this fundamental experiment could lead to science-fiction-like medical advancements, where organ regeneration becomes a reality in both deep space and here on Earth.”

Researchers at HMRI will take the results from UTMB and work on developing therapeutics that could help astronauts, as well as people on Earth.

“This exploration will provide fundamental insight for the collaborative development of cell-based therapies for autoimmune diseases, hormone deficiencies and other issues,” Grattoni said.

Explore further: Image: Testing astronauts’ lung health

Link:
Lungs in space: research project could lead to new lung therapeutics – Phys.Org

Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

For cancer patients, understanding the odds of a treatments success can be bewildering. The same drug, applied to the same type of cancer, might be fully successful on one persons tumour and do nothing for another one. Physicians are often unable to explain why.

Now, U of T Engineering researchers are beginning to understand one of the reasons.Abdullah Syed and Shrey Sindhwani, both PhD candidates,and their colleagues at the Institute of Biomaterials & Biomedical Engineering (IBBME) have created a technology to watch nanoparticles traveling into tumours revealing barriers that prevent their delivery to targets and the variability between cancers.

The biggest thing weve noticed is that nanoparticles face multiple challenges posed by the tumour itself on their way to cancer cells, says Sindhwani, an MD-PhD student in the Integrated Nanotechnology & Biomedical Sciences Laboratory of Professor Warren Chan (IBBME). Syed and Sindhwani co-published their findings online June 22, and on the cover of the Journal of the American Chemical Society. So the treatment might work for a while or worse, theres just enough of the drug for the cancer to develop resistance. This could be prevented if we can figure out the ways in which these barriers stop delivery and distribution of the drug throughout the cancer.

Tiny nanoparticles offer great hope for the treatment of cancer and other disease because of their potential to deliver drugs to targeted areas in the body, allowing more precise treatments with fewer side effects. But so far the technology hasnt lived up to its promise, due to delivery and penetration problems.

To dismantle this roadblock, the two graduate students searched for a way to better view the particles journey inside tumours. They discovered that the tough-to-see particles could be illuminated by scattering light off their surfaces.

The sensitivity of our imaging is about 1.4 millionfold higher, says Syed. First, we make the tissue transparent, then we use the signal coming from the particles to locate them. We shine a light on the particles and it scatters the light. We capture this scattering light to learn the precise location of the nanoparticles.

It was already understood that nanoparticles were failing to accumulate in tumours, thanks to a meta-analysis of the field done by Chans group. But the researchers have developed technologies to look at nanoparticle distribution in 3D, which provides a much fuller picture of how the particles are interacting with the rest of the tumour biology. The goal is to use this technology to gather knowledge for developing mathematical principles of nanoparticle distribution in cancer, similar to the way principles exist for understanding the function of the heart, says Syed.

And because each tumour is unique, this technology and knowledge base should help future scientists to understand the barriers to drug delivery on a personalized basis, and to develop custom treatments.

The next step is to understand what in cancers biology stops particles from fully penetrating tumours and then to develop ways to bypass cancers defences.

But the technology is also useful for diseases other than cancer. With the help of Professor Jennifer Gommerman, an researcher in the Department of Immunology who studies multiple sclerosis (MS), Syed and Sindhwani captured 3D images of lesions in a mouse model mimicking MS using nanoparticles.

This is going to be very valuable to anyone trying to understand disease or the organ system more deeply, says Sindhwani. And once we understand barriers that dont allow drugs to reach their disease site, we can start knocking them down and improving patient health adds Syed.

See original here:
Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

‘Nanomedicine’: Potentially revolutionary class of drugs are made-in-Canada – CTV News

It’s rare for researchers to discover a new class of drugs, but a University of Calgary microbiology professor recently did so — by accident and now hopes to revolutionize autoimmune disease treatment.

In 2004, Dr. Pere Santamaria and his research lab team at the Cumming School of Medicine conducted an experiment to image a mouse pancreas, using nanoparticles coated in pancreatic proteins.

The work didnt go as planned.

Our experiment was a complete failure, he recently told CTV Calgary. We were actually quite depressed, frustrated about the outcome of that.

But the team was surprised to discover the nanoparticles had a major effect on the mice: resetting their immune systems.

The team realized that, by using nanoparticles, they can deliver disease-specific proteins to white blood cells, which will then go on to reprogram the cells to actively suppress the disease.

Whats more, the nanoparticles stop the disease without compromising the immune system, as current treatments often do.

Santamarias team believes nanomedicine drugs can be modified to treat all kinds of autoimmune and inflammatory diseases, including Type 1 diabetes, multiple sclerosis and rheumatoid arthritis.

Convinced that nanomedicine has the potential to disrupt the pharmaceutical industry, Santamaria founded a company to explore the possibilities, called Parvus Therapeutics Inc.

This past spring, Novartis, one of the worlds largest pharmaceutical companies, entered into a license and collaboration agreement with Parvus to fund the process of developing nanomedicine.

Under the terms of the agreement, Parvus will receive research funding to support its clinical activities, while Novartis receives worldwide rights to use Parvus technology to develop and commercialize products for the treatment of type 1 diabetes.

Its a good partnership, Santamaria said in a University of Calgary announcement. Bringing a drug to market requires science as well as money.

Santamaria cant say how long it might be before nanomedicine can be used to create human therapies, but he says everyone involved is working aggressively to make it happen.

With a report from CTV Calgarys Kevin Fleming

Follow this link:
‘Nanomedicine’: Potentially revolutionary class of drugs are made-in-Canada – CTV News

UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News

When Dr. Pere Santamaria arrived in Calgary in 1992 to join the Cumming School of Medicine, he never could have imagined he would make a groundbreaking discovery that would lead to a spinoff company. When I arrived, I found out that the grant money I was expecting hadnt come through, says Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases and member of the Snyder Institute for Chronic Diseases. So I had an empty lab with no research assistants and no salary. I had to beg my supervisor to give me $10,000 to start my research.

Despite the rocky start, Santamaria has achieved something many scientists dream of making a discovery that has practical applications for health care. Santamarias discovery revolves around the use of nanoparticles coated in proteins to treat autoimmune and inflammatory disorders.

They can be modified for different diseases, such as Type 1 diabetes, multiple sclerosis and rheumatoid arthritis without compromising the entire immune system, Santamaria explains. Instead, they basically work to reset the immune system.

Nanomedicines unique mechanism has the potential to disrupt the pharmaceutical industry entirely. Developing a new class of drugs is rare. With the assistance of Innovate Calgary, Santamaria started a company, Parvus Therapeutics Inc., to represent the technology and explore ways of bringing it to market. Announced in April 2017, Parvus entered into an exclusive deal with the Swiss pharma giant Novartis, hopefully leading to the development and commercialization of Parvuss nanomedicine to treat Type 1 diabetes.

Its a good partnership, Santamaria says. Bringing a drug to market requires science as well as money.

Supporting commercialization should be a top priority for all research, he continues. Our biggest responsibility is to the patients and making sure they have access to the medicine they need. With that in mind, Santamaria shares his insight for other researchers who may be interested in bringing their discoveries from the lab bench to the market.

If youre interested in investigating spin-out opportunities, get in touch with Innovate Calgary, which offers mentors, coaching, business skill development programs, intellectual property services and other back-office support.

Throughout the years, Santamarias work has been funded by numerous organizations, including Diabetes Canada, the Juvenile Diabetes Research Foundation, the Canadian Institutes of Health Research (CIHR) and the Diabetes Association, Foothills.He is a member of the Snyder Institute and associate member of the Hotchkiss Brain Institute.Santamaria named his company Parvus from the Greek word meaning small.

Original post:
UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News


12345...10...